Xanthohumol ameliorates dextran sodium sulfate-induced colitis in mice by inhibiting of NF-κB signaling pathways and modulating intestinal microbiota
- PMID: 39576384
- DOI: 10.1007/s00394-024-03525-5
Xanthohumol ameliorates dextran sodium sulfate-induced colitis in mice by inhibiting of NF-κB signaling pathways and modulating intestinal microbiota
Abstract
Ethnopharmacological relevance: Xanthohumol (XN), an isoprenylated flavonoid natural product found only in hops, possesses a variety of biological activities such as anticancer, anti-inflammatory, hepatoprotective, and anti-obesity.
Aim of the study: The aim of this study was to investigate the effects and mechanisms of XN on the treatment of colitis.
Materials and methods: First, acute colitis was induced by using distilled water containing 3% DSS for 10 consecutive days. The therapeutic efficacy of XN was assessed by an established DSS-induced mouse colitis model. Subsequently, disease activity index (DAI) and colon length of mice were assessed. The health of the intestines was assessed by histopathological analysis. Inflammatory factors, IL-1β, IL-6, and TNF-α, were detected in colon tissues by ELISA.Finally, mouse intestinal contents were extracted and subjected to 16 S rRNA Sequencing, and the gut microbiota was analysed for Alpha-diversity and Beta-diversity.
Results: The results showed that XN ameliorated DSS-induced colitis. Furthermore, XN reduced pro-inflammatory cytokine levels such as IL-1β, IL-6, and TNF-α, as well as inhibited the activation of the TLR4/NF-κB pathway, all of which helped to mitigate the inflammatory response. Finally, we also found that XN alleviated intestinal dysbiosis in colitis mice.
Conclusion: In conclusion, our study demonstrated that XN provides protective effects against colitis, and has the potential to be further explored as a lead compound for the treatment of inflammatory bowel disease (IBD).
Keywords: Colitis; Inflammatory bowel disease; Intestinal microbiota; NF-κB; Xanthohumol.
© 2024. Springer-Verlag GmbH Germany, part of Springer Nature.
Conflict of interest statement
Declarations. Conflict of interest: The authors have no conflicts of interest to declare.
Similar articles
-
Canna x generalis L.H. Bailey rhizome extract ameliorates dextran sulfate sodium-induced colitis via modulating intestinal mucosal dysfunction, oxidative stress, inflammation, and TLR4/ NF-ҡB and NLRP3 inflammasome pathways.J Ethnopharmacol. 2021 Apr 6;269:113670. doi: 10.1016/j.jep.2020.113670. Epub 2020 Dec 8. J Ethnopharmacol. 2021. PMID: 33301917
-
Astragalin Attenuates Dextran Sulfate Sodium (DSS)-Induced Acute Experimental Colitis by Alleviating Gut Microbiota Dysbiosis and Inhibiting NF-κB Activation in Mice.Front Immunol. 2020 Sep 15;11:2058. doi: 10.3389/fimmu.2020.02058. eCollection 2020. Front Immunol. 2020. PMID: 33042117 Free PMC article.
-
Saikosaponin-d ameliorates dextran sulfate sodium-induced colitis by suppressing NF-κB activation and modulating the gut microbiota in mice.Int Immunopharmacol. 2020 Apr;81:106288. doi: 10.1016/j.intimp.2020.106288. Epub 2020 Feb 13. Int Immunopharmacol. 2020. PMID: 32062075
-
A Novel Look at Mechanisms and Applications of Xanthohumol (XN) in Dermatology and Cosmetology.Int J Mol Sci. 2024 Nov 6;25(22):11938. doi: 10.3390/ijms252211938. Int J Mol Sci. 2024. PMID: 39596008 Free PMC article. Review.
-
Is there a place for natural agents with anti-inflammatory and antioxidative properties in critically ill patients? Potential usefulness of Xanthohumol.Pharmacol Ther. 2025 Feb;266:108766. doi: 10.1016/j.pharmthera.2024.108766. Epub 2024 Dec 3. Pharmacol Ther. 2025. PMID: 39637948 Review.
References
-
- Mulder DJ, Noble AJ, Justinich CJ, Duffin JM (2014) A tale of two diseases: the history of inflammatory bowel disease. J Crohns Colitis 8(5):341–348. https://doi.org/10.1016/j.crohns.2013.09.009 - DOI - PubMed
-
- Papamichael K, Afif W, Drobne D, Dubinsky MC, Ferrante M, Irving PM, Kamperidis N, Kobayashi T, Kotze PG, Lambert J, Noor NM, Roblin X, Roda G, Vande Casteele N, Yarur AJ, Arebi N, Danese S, Paul S, Sandborn WJ, Vermeire S, Cheifetz AS, Peyrin-Biroulet L (2022) Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives. Lancet Gastroenterol Hepatol 7(2):171–185. https://doi.org/10.1016/S2468-1253(21)00223-5 - DOI - PubMed - PMC
-
- Shan Y, Lee M, Chang EB (2022) The gut Microbiome and Inflammatory Bowel diseases. Annu Rev Med 73:455–468. https://doi.org/10.1146/annurev-med-042320-021020 - DOI - PubMed
-
- Wu Z, Huang S, Li T, Li N, Han D, Zhang B, Xu ZZ, Zhang S, Pang J, Wang S, Zhang G, Zhao J, Wang J (2021) Gut microbiota from green tea polyphenol-dosed mice improves intestinal epithelial homeostasis and ameliorates experimental colitis. Microbiome 9(1):184. https://doi.org/10.1186/s40168-021-01115-9 - DOI - PubMed - PMC
MeSH terms
Substances
Grants and funding
LinkOut - more resources
Full Text Sources
Research Materials